We believe that bringing the power of today’s technology together with tenured clinical experts is the winning combination for building a platform that can deliver the healthcare outcomes Americans need and deserve. Today, more than two million customers1 trust Hims & Hers daily with their care. Through their experiences on our platform, we know that it has never been more true that the time is now for high-quality, accessible, affordable, personalized care for people across the country.
To kick off 2025, here’s what we should expect to see build and progress over the next year in the way Americans access and receive care:
Healthcare is currently one of the only industries where the consumer’s voice isn’t the most important voice in the room: in areas like personal finance, consumers are empowered to make their own informed decisions about what is right for them and their families based on a breadth of choices and transparent pricing. That should be true in healthcare, and I expect that we’ll see an increase in customers’ ability to choose and access affordable, quality healthcare in the way that works best for their unique situation.
That can mean using telehealth to access care for conditions that don’t require in-person visits, working with a licensed prescriber to access a personalized version of their medication to increase their adherence to a treatment, or choosing a lower cost version of a medication without sacrificing results. As conversations around patient choice drive policy at the highest levels of our government, we’ll see that individuals seeking care – not federal agencies, not drugmakers, not payers – will take their ability to control their own care more seriously.
We’re anticipating this shift and delivering solutions that answer to that need. This can include introducing new form factors that allow customers to manage their treatment in the most convenient, comfortable way for them.
More and more women are sharing their experiences around their health as they go through different life stages and the conversation is shifting: as more women speak out, the stigma surrounding menopause is decreasing, making room for more nuanced conversations around treatments.
I expect this will be the 2025 version of past healthcare condition booms like we’ve seen in men’s sexual performance, hair loss, and weight loss, and more options for women navigating this life stage will come onto the scene.
We’ve previously used the combination of reducing stigma and increasing access to our other categories, like dermatology, sexual health, mental health, and weight loss. Perimenopause and menopause is a natural next step for us. Personalization and accessibility for our customers is always a focus, but in this condition specifically, we believe it starts with providers: by giving licensed providers on our platform a way to prescribe compounded treatments for their patients, we’re giving them a deeper ability to care for an individual’s experience, rather than simply a list of symptoms. Our approach means high-quality care can scale, and in an area like menopause, where more than half of the population will need support at some point in their lives, achieving that scale means we’ll be able to help people who may have been left out of the system in the past.
Healthcare has been slow to adopt technology in ways that actually scale impact, improve care, and increase access to care. That includes intelligent, predictive AI that can improve the accuracy of recommendations and impacts of treatment. Currently, most of the patient impacts from AI-enabled models are decreased wait times and getting patients closer to providers. That’s valuable in a world where primary care physicians feel like a luxury and wait times are longer than ever – but that is just the beginning of what AI can do for patients seeking care.
This year, incorporating AI into how patients engage and receive their care will enable world-class, high-quality personalized care to every individual, regardless of their income, their location, or their condition. Our current healthcare system is archaic: we rely on a single opinion from a single provider to decide what is best for our unique situation. That opinion is, of course, formed by the valuable years of the provider’s education and experience, but it is limited to only that provider’s education and experience. Even in the event that a patient seeks out a second opinion, healthcare decisions are being made inside the limitations of a few providers. AI has the power to bring the expertise of millions of providers to a single customer – rather than simply allowing a single provider to reach more individuals.
We built MedMatch to give providers on the Hims & Hers platform a more intelligent and informed way to deliver personalized care to patients with more effective and precise treatments and medications. The technology allows providers to leverage the collective knowledge of their peers from across the country, as well as millions of de-identified data points from interactions on our platform, to find the best solution for their patients. It’s like getting a thousandth opinion, instead of just a second opinion. This will allow our customers to get much closer to care that is tailored exactly to who they are as an individual – not just the care that is the standard for everyone of their demographic or geographic location.
More than two-thirds of American adults are overweight or obese, and 1 in 6 deaths in the US are related to obesity. This is a public health crisis and it is only going to get worse if we don't push to make effective solutions accessible and affordable. GLP-1s have the power to change what obesity means in this country, but while the industry is squabbling over patents and arbitrary ends to very real shortages, millions of Americans are struggling to access the consistent, effective and affordable care they need. We have the tools to change the trajectory of this crisis and it’s a matter of the system coming together to take care of the people who need and deserve it.
The kinds of conditions GLP-1s can impact grows every day: studies have shown they can impact kidney disease, heart disease, and sleep apnea, and we’ve seen promising results around other conditions that impact nearly every American family, like addiction. With the size of our platform and the expertise of our team, Hims & Hers has the responsibility to advocate for our customers, deliver a safe, effective, high-quality customer experience that leads to the outcomes they want to see, and continue to push our peers in the industry to prioritize the crises facing our customers daily.
Healthcare is transforming to be more consumer-centric, and Hims & Hers is leading that transformation. We believe every individual should be able to access and afford care designed for their individual goals and needs. In 2025, I expect more innovation and evolution to come to the healthcare industry, and it will all be centered on getting each person closer to the kind of care that changes their lives, rather than maintaining the status quo. I can’t wait to see how Hims & Hers is part of that sea change.
1As of the end of the third quarter of 2024.
Forward-Looking Statements
This newsroom post includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “project,” “confidence,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line revenue growth and profitability and our ability to attain our medium- and long-term financial targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, strategy, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix (including compounded, generic or branded GLP-1 medications), the timing and market acceptance of any new products or offerings (including offerings for the treatment of menopause), the timing and anticipated effect of any pending acquisitions, the success of our business model, our market opportunity, our ability to scale our business, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, including through the use of data analytics and artificial intelligence, our ability to reinvest into the customer experience, and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of any litigation or governmental actions that may arise in relation to any such legal and regulatory requirements. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this letter are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”).
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Any forward-looking statement made by us in this post is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.
We include statements and information in this post concerning our industry and the markets in which we operate, including our market opportunity, which are based on information from independent industry organizations and other third-party sources (including industry publications, surveys and forecasts). While we believe these third-party sources to be reliable as of the date of this letter, we have not independently verified any third-party information and such information is inherently imprecise.
